Shetty AM et al., 2007-12: MRI versus gross pathology comparison of convectively delivered injectate in canine prostates, with methylene blue used as the visibly stained surrogate drug marker (3 ex vivo and 12 in vivo glands).
Canine prostates (ex vivo, n = 3; in vivo, n = 12) were injected under several injection paradigms with a solution of gadolinium-DTPA for MR contrast and methylene blue as a grossly visible surrogate drug marker.
Shetty AM et al., 2007-12: MRI versus gross pathology comparison of convectively delivered injectate in canine prostates, with methylene blue used as the visibly stained surrogate drug marker (3 ex vivo and 12 in vivo glands). C4. Study type: animal (canine prostate, ex vivo and in vivo), methods. N: 3 ex vivo + 12 in vivo prostates. Country: USA (MD Anderson Cancer Center). Methylene blue: injected with gadolinium-DTPA as the grossly visible marker; concentration not stated in the abstract. Funder: NCI CA 16672 per GrantList. Conflicts: none declared. Comparator: MRI fractional volume vs methylene blue pathology photographs (R = 0.99 ex vivo, 0.77 in vivo). Study type: animal.
